The approvals of Wegovy (2021) and tirzepatide (Mounjaro, 2022
Jeong SJ, Lee SE, Shin DH, Park IB, Lee HS, Kim K-A
BCBS Michigan changed the prior authorization criteria for Zepbound (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide) from August 1, 2024, through December 31, 2024
Key protective strategies include: Pre-treatment ophthalmologic evaluation : Establish baseline retinal status before initiating GLP-1 therapy, particularly in patients with diabetes duration exceeding 10 years or poor prior glycemic control Individualized medication titration : Consider a more gradual dose escalation approach to avoid precipitous drops in blood glucose for patients with advanced diabetic retinopathy, in coordination with ophthalmology care Appropriate monitoring : Discuss with your healthcare provider whether more frequent eye examinations are needed based on your individual risk factors and baseline retinal status Prompt reporting of visual symptoms : Contact your healthcare provider immediately if you experience sudden vision loss, new or dense floaters, flashing lights, a "curtain" over your vision, eye pain with vision changes, or any sudden vision disturbance Patients without pre-existing diabetic retinopathy can generally follow standard eye examination schedules and do not require additional ophthalmologic monitoring solely due to GLP-1 use
GLP-1 programs that are provided by physicians via telehealth indicate the increasing need in medically-monitored weight-loss programs
289711-21-3 Molecular Weight 484.61 Formula C 16 H 28 N 4 O 7 S 3 SMILES OC([C@@H](N)CCC(N[C@@H](CSC(NCCCCS(C)=O)=S)C(NCC(O)=O)=O)=O)=O Synonyms DL-SFN-GSH Shipping Room temperature in continental US
